Overview

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

Status:
Unknown status

Trial end date:
2020-07-07

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic cervical cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Biocad

Treatments:

Bevacizumab
Carboplatin
Paclitaxel